tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Alcon (ALC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eli Lilly & Co (LLYResearch Report) and Alcon (ALCResearch Report) with bullish sentiments.

Eli Lilly & Co (LLY)

Mizuho Securities analyst Vamil Divan reiterated a Buy rating on Eli Lilly & Co yesterday and set a price target of $293.00. The company’s shares closed last Tuesday at $243.84.

According to TipRanks.com, Divan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -3.4% and a 45.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, ACADIA Pharmaceuticals, and Xeris Pharmaceuticals.

Eli Lilly & Co has an analyst consensus of Moderate Buy, with a price target consensus of $289.94, a 22.5% upside from current levels. In a report issued on February 3, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $335.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Alcon (ALC)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Alcon yesterday and set a price target of $92.00. The company’s shares closed last Tuesday at $78.83.

According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 15.5% and a 47.6% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Organogenesis Holdings, Zimmer Biomet Holdings, and Integra Lifesciences.

Alcon has an analyst consensus of Moderate Buy, with a price target consensus of $89.09.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LLY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed